Tags Archive Navigation
icon
-
Media ReleaseNovartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
-
Media ReleaseNovartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia
-
Media ReleaseNovartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience
-
Media ReleaseNovartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
-
Media ReleaseNovartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
-
Media ReleaseAveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
-
Media ReleaseZolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
-
Media ReleaseAveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
-
Media ReleaseNovartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
-
Media ReleaseAveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
-
StoryResearchers boost understanding of T-cell therapy in blood cancer
-
StoryHardwiring the future